These innovative compounds represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose https://larissajmuw970608.digitollblog.com/39037984/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide